FI922609A - Proteiner och nukleinsyror. - Google Patents

Proteiner och nukleinsyror. Download PDF

Info

Publication number
FI922609A
FI922609A FI922609A FI922609A FI922609A FI 922609 A FI922609 A FI 922609A FI 922609 A FI922609 A FI 922609A FI 922609 A FI922609 A FI 922609A FI 922609 A FI922609 A FI 922609A
Authority
FI
Finland
Prior art keywords
pct
syror
proteiner
nuclein
och
Prior art date
Application number
FI922609A
Other languages
English (en)
Finnish (fi)
Other versions
FI922609A0 (fi
Inventor
Keith Martyn Dawson
Michael George Hunter
Lloyd George Czaplewski
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Publication of FI922609A0 publication Critical patent/FI922609A0/fi
Publication of FI922609A publication Critical patent/FI922609A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C12N2830/704—S. cerevisiae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/107—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translational read-through

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI922609A 1989-12-07 1992-06-05 Proteiner och nukleinsyror. FI922609A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927722A GB8927722D0 (en) 1989-12-07 1989-12-07 Proteins and nucleic acids
PCT/GB1990/001911 WO1991009125A1 (fr) 1989-12-07 1990-12-07 Proteines et acides nucleiques

Publications (2)

Publication Number Publication Date
FI922609A0 FI922609A0 (fi) 1992-06-05
FI922609A true FI922609A (fi) 1992-06-05

Family

ID=10667597

Family Applications (2)

Application Number Title Priority Date Filing Date
FI922609A FI922609A (fi) 1989-12-07 1992-06-05 Proteiner och nukleinsyror.
FI922610A FI105202B (fi) 1989-12-07 1992-06-05 Menetelmä aktivoitavien fibrinolyyttisten ja veren hyytymistä estävien plasminogeenianalogien valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI922610A FI105202B (fi) 1989-12-07 1992-06-05 Menetelmä aktivoitavien fibrinolyyttisten ja veren hyytymistä estävien plasminogeenianalogien valmistamiseksi

Country Status (21)

Country Link
US (2) US5434073A (fr)
EP (2) EP0502968B1 (fr)
JP (2) JP2851423B2 (fr)
KR (2) KR920703818A (fr)
AT (1) ATE155812T1 (fr)
AU (3) AU644399B2 (fr)
CA (2) CA2069085C (fr)
DE (1) DE69031127T2 (fr)
DK (1) DK0502968T3 (fr)
ES (1) ES2106073T3 (fr)
FI (2) FI922609A (fr)
GB (1) GB8927722D0 (fr)
GR (1) GR3024990T3 (fr)
HU (1) HU211628A9 (fr)
IE (2) IE81046B1 (fr)
IL (2) IL96601A (fr)
NO (2) NO305562B1 (fr)
NZ (2) NZ236330A (fr)
PT (2) PT96103B (fr)
WO (2) WO1991009125A1 (fr)
ZA (2) ZA909854B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22277A1 (es) * 1990-05-23 1995-01-31 Cigb Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
GB9216558D0 (en) * 1992-08-04 1992-09-16 British Bio Technology Modified proteases
GB2286190B (en) * 1992-10-29 1996-05-01 British Biotech Pharm Thrombin activatable plasminogen derivatives
DE4323754C1 (de) * 1993-07-15 1994-12-01 Gruenenthal Gmbh Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
JPH08502661A (ja) * 1993-08-04 1996-03-26 チバ−ガイギー アクチェンゲゼルシャフト 高分子量デスルファトヒルジン
ES2080657B1 (es) * 1993-09-27 1996-11-01 Britisch Bio Technology Limite Proteasas modificadas.
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN1309833C (zh) * 1994-04-26 2007-04-11 儿童医学中心公司 血管生成抑制素及其在制备药物中的用途
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
KR20000029755A (ko) * 1996-08-02 2000-05-25 로셰 디아그노스틱스 게엠베하 트롬빈에의해활성화될수있는플라스미노겐활성화제
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
ATE203567T1 (de) * 1998-03-19 2001-08-15 Instrumentation Lab Spa Verbesserte in vitro verfahren, testkits und reagenzien zum screening von blutgerinnungsfehlern
AU5571799A (en) 1998-08-20 2000-03-14 University Of Vermont And State Agricultural College, The Angiogenesis inhibitors and uses thereof
IN190822B (fr) * 1998-12-24 2003-08-23 Council Scient Ind Res
WO2001036351A2 (fr) 1999-11-19 2001-05-25 Corvas International, Inc. Antagonistes de l'inhibiteur des activateurs du plasminogène
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU8591901A (en) * 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
DE10108212A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108100A1 (de) * 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10108211A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
US7638618B2 (en) * 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
EP1572908A4 (fr) * 2002-02-14 2008-10-22 William J Rutter Molecules chimeriques permettant d'administrer un clivage a un hote traite
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
EP1867660A1 (fr) 2006-06-14 2007-12-19 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
GB2455262A (en) * 2006-09-29 2009-06-10 Proteomtech Inc Methods for production of recombinant plasminogen and plasmin polypeptides
CN1970574B (zh) * 2006-12-08 2010-08-25 中国药科大学 溶栓和抗凝双重功效融合蛋白、制备方法及其应用
EP2097096B1 (fr) 2006-12-22 2017-05-31 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
EP2396347B1 (fr) 2009-02-11 2017-04-12 Albumedix A/S Variants et conjugés de l'albumine
CA2770980A1 (fr) * 2009-07-15 2011-01-20 Roger Y. Tsien Peptides dont l'absorption par les cellules peut etre regulee
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
US9150844B2 (en) * 2010-08-05 2015-10-06 Neeraj Maheshwari Protein fusion constructs possessing thrombolytic and anticoagulant properties
WO2013019681A2 (fr) 2011-07-29 2013-02-07 Avelas Biosciences, Inc. Molécules de délivrance sélective et procédés d'utilisation
AU2012296884B2 (en) 2011-08-12 2015-02-05 Thrombogenics N.V. Plasminogen and plasmin variants
WO2013075066A2 (fr) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
WO2013135896A1 (fr) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Variants d'albumine
WO2014072481A1 (fr) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Variants d'albumine
WO2014120837A2 (fr) 2013-01-29 2014-08-07 The Regents Of The University Of California Peptide à pénétration cellulaire activable pré-ciblé comportant un promédicament à libération intracellulaire
KR102278630B1 (ko) 2013-01-30 2021-07-16 아벨라스 바이오사이언시즈 인코포레이티드 선택적 전달 분자 및 사용 방법
WO2014125082A1 (fr) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Modèle pharmacocinétique animal
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1897087A (en) * 1927-12-14 1933-02-14 Tamarin Bernard Jacques Vacuum cleaner cord control device
US3608333A (en) * 1968-06-20 1971-09-28 Bison Mfg Co Inc Vacuum cleaner and power unit
US4880776A (en) * 1983-12-24 1989-11-14 Beecham Group P.L.C. Plasmin A-chain urokinase B-chain hybrid protein
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
DE3410437A1 (de) * 1984-03-22 1985-09-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von proteinen
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5200340A (en) * 1987-05-22 1993-04-06 Zymogenetics, Inc. Thrombin-activated tissue plasminogen activators
EP0292009A1 (fr) * 1987-05-22 1988-11-23 Zymogenetics, Inc. Protéines fibrinolytiques
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
DE3883453T2 (de) * 1987-07-01 1994-03-17 Beecham Group Plc Hybride Plasminogenaktivatoren.
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1340802C (fr) * 1987-08-15 1999-10-26 Yasuyuki Takahashi Proteine precurseur de l'amyloide senile et anticorps specifique pour cette proteine
DE3886517T2 (de) * 1987-08-19 1994-04-21 Sagami Chem Res Menschlicher Prourokinase ähnliches Polypeptid.
CA1340740C (fr) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Coexpressiondans des cellules eucaryotes
CA1340877C (fr) * 1987-12-28 2000-01-18 Takashi Sugiyama Polypeptide inhibant l'elastage et procede de production par la technologie de l'adn recombinant
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
JPH04505554A (ja) * 1989-02-17 1992-10-01 コドン 可溶性トロンボモジュリン類似体
JPH05500748A (ja) * 1989-05-01 1993-02-18 ザ　ユニバーシティ　オブ　ノートル　ダム　デュ　ラック 真核細胞系でのヒトプラスミノーゲンの発現方法および物質
US5164304A (en) * 1989-05-04 1992-11-17 Sri International Method and vectors for stabilizing hirudin and human laminin b1 expression
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
EP0561034B1 (fr) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Clonage moléculaire direct d'un génome modifié d'un virus chordopox

Also Published As

Publication number Publication date
PT96103A (pt) 1991-09-30
ZA909854B (en) 1992-08-26
CA2069085C (fr) 2000-02-01
EP0502968A1 (fr) 1992-09-16
GB8927722D0 (en) 1990-02-07
HU211628A9 (en) 1995-12-28
FI105202B (fi) 2000-06-30
WO1991009118A2 (fr) 1991-06-27
PT96103B (pt) 1998-08-31
KR920703818A (ko) 1992-12-18
ES2106073T3 (es) 1997-11-01
GR3024990T3 (en) 1998-01-30
IE81046B1 (en) 1999-12-01
FI922610A (fi) 1992-06-05
PT96104A (pt) 1991-09-30
AU6965691A (en) 1991-07-18
EP0504241A1 (fr) 1992-09-23
IL96601A0 (en) 1991-09-16
AU644399B2 (en) 1993-12-09
NZ236330A (en) 1993-05-26
ZA909853B (en) 1992-08-26
NO922237D0 (no) 1992-06-05
WO1991009125A1 (fr) 1991-06-27
ATE155812T1 (de) 1997-08-15
NO922237L (no) 1992-08-06
CA2069085A1 (fr) 1991-06-08
IE904417A1 (en) 1991-06-19
JPH05502374A (ja) 1993-04-28
DE69031127T2 (de) 1998-02-05
DK0502968T3 (da) 1998-03-02
NO922238D0 (no) 1992-06-05
NO305562B1 (no) 1999-06-21
AU4497693A (en) 1993-11-18
IL96601A (en) 1999-05-09
US5637492A (en) 1997-06-10
FI922609A0 (fi) 1992-06-05
CA2069105A1 (fr) 1991-06-08
EP0502968B1 (fr) 1997-07-23
WO1991009118A3 (fr) 1991-10-31
AU6954091A (en) 1991-07-18
IE904416A1 (en) 1991-07-17
AU643247B2 (en) 1993-11-11
NO922238L (no) 1992-08-06
US5434073A (en) 1995-07-18
IL96602A0 (en) 1992-05-25
DE69031127D1 (de) 1997-09-04
NZ236401A (en) 1992-03-26
FI922610A0 (fi) 1992-06-05
JP2851423B2 (ja) 1999-01-27
KR100188302B1 (ko) 1999-06-01
KR920703803A (ko) 1992-12-18
JPH05502375A (ja) 1993-04-28

Similar Documents

Publication Publication Date Title
FI922610A0 (fi) Aktiverbara fibrinolytidka och anti- trombotiska proteiner.
Stern et al. An endothelial cell-dependent pathway of coagulation.
ATE307111T1 (de) Serinprotease-inhibitoren
Seegers Antithrombin III. Theory and Clinical Applications: HP Smith Memorial Lecture
DE60122750D1 (de) Amidine-inhibitoren der serine-proteasen
Gertler et al. Prothrombotic and fibrinolytic function of normal and perturbed endothelium
SE8301795D0 (sv) Plasminogenaktivatorkomplex
Hoffman et al. Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes
Pâques et al. Comparative study on the in vitro effectiveness of antithrombotic agents
Geratz et al. Current concepts on action of synthetic thrombin inhibitors
Fukao et al. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation
FI932196A (fi) Foerfarande foer bestaemning av fibrinogen
DE69018361D1 (de) Phosphorylierte plasminogenaktivatoren.
Stief et al. Specificity of functional determination of urokinase in human plasma using selective oxidants
Hanemaaijer et al. Inhibition of urokinase-type and tissue-type plasminogen activator—mediated plasminogen activation by doxycycline
UA10374C2 (uk) Спосіб визhачеhhя вмісту фібриhогеhу в плазмі крові при гепариhотерапії